The Effect of a Single Midcycle Administration of 0.5 or 2.0 mg Dienogest (17α-cyanomethyl- 17β-hydroxy-estra-4, 9-dien-3-one)on Pituitary and Ovarian Function - Investigation for the Use as a Postcoital Contraceptive1)

Günter Köhler, G Görétzlehner, K Rudolf, M Rüting, J. Meißner, S Kunkel, K Schollberg
In: Experimental and Clinical Endocrinology & Diabetes · 2009 · vol. 84(06) , pp. 299–304 · doi:10.1055/s-0029-1210402 · PMID:6441728 · W2057255025
article OA: closed CC0 ⤵ 6 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-14 ⓘ

A single midcycle dose of dienogest altered pituitary and ovarian function, with 2.0 mg delaying the LH surge and suppressing ovulation, and 0.5 mg in the follicular phase causing anovulation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text ⓘ

The study measured plasma estradiol-17β, progesterone, LH, and FSH levels by radioimmunoassay and recorded basal body temperature to assess how a single midcycle oral dose of dienogest (0.5 mg or 2.0 mg) affects pituitary and ovarian function in 18 healthy fertile women. Dienogest timing relative to the LH surge was key: 0.5 mg in the follicular phase was associated with anovulatory cycles, while 2.0 mg given two days before the expected LH surge delayed the LH peak and prevented ovulation and the subsequent progesterone rise; in contrast, 0.5 mg given two days prior delayed the LH surge but still allowed ovulation with normal corpus luteum function. Dosing one day before or during the rising LH peak lowered the LH surge without altering ovulation or luteal phase, and administration during the LH peak did not prevent ovulation or disturb corpus luteum function. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Estradiol-17 beta, progesterone, LH and FSH levels in plasma were measured simultaneously by radioimmunoassay and BBT was recorded in order to investigate the effect of a single midcycle oral dose of 0.5 or 2.0 mg dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one, VEB Jenapharm, Jena/GDR) on pituitary and ovarian function in 18 healthy fertile females. After application of 0.5 mg dienogest in the follicular phase the cycles appeared to be anovulatory. Administration of 2.0 mg two days prior to the expected LH-surge produced a delay of the LH-peak combined with an absence of ovulation as well as the absence of the normal subsequent increase of progesterone. With 0.5 mg the delay of the LH-surge was followed by an ovulation with normal corpus luteum function. The application of 0.5 or 2.0 mg one day before or during the rising LH-peak lowered the LH-surge but ovulation and luteal phase were not altered. Administration of both dosages during the LH-peak could neither prevent ovulation nor disturb corpus luteum function. Postovulatory ingestion of 0.5 or 2.0 mg dienogest during the BBT-rise produced no alteration of the further cycle. These results demonstrate that dienogest in a single-dose-administration in midcycle can alter pituitary and ovarian function depending on the time interval between application and the day of LH-surge.
Full text 1,880 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS DOI: 10.1055/s-0029-1210402 © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York The Effect of a Single Midcycle Administration of 0.5 or 2.0 mg Dienogest (17α-cyanomethyl- 17β-hydroxy-estra-4, 9-dien-3-one)on Pituitary and Ovarian Function - Investigation for the Use as a Postcoital Contraceptive1) 1) In co-operation with VEB Jenapharm, Jena, GDRPublication History 1983 Publication Date: 17 July 2009 (online) Summary Estradiol-17β, progesterone, LII and FSH levels in plasma were measured simultaneously by radioimmunoassay and BBT was recorded in order to investigate the effect of a single midcycle oral dose of 0.5 or 2.0 mg dienogest (17α-cyanomethyl-17β-hydroxy-estra-4,9-dien-3-one, VEB Jenapharm, Jena/GDR) on pituitary and ovarian function in 18 healthy fertile females. After application of 0.5 mg dienogest in the follicular phase the cycles appeared to be anovulatory. Administration of 2.0 mg two days prior to the expected LH-surge produced a delay of the LH-peak combined with an absence of ovulation as well as the absence of the normal subsequent increase of progesterone. With 0.5 mg the delay of the LH-surge was followed by an ovulation with normal corpus luteum function. The application of 0.5 or 2.0 mg one day before or during the rising LHpeak lowered the LH-surge but ovulation and luteal phase were not altered. Administration of both dosages during the LH-peak could neither prevent ovulation nor disturb corpus luteum function. Postovulatory ingestion of 0.5 or 2.0 mg dienogest during the BBT-rise produced no alteration of the further cycle. These results demonstrate that dienogest in a single-dose-administration in midcycle can alter pituitary and ovarian function depending on the time interval between application and the day of LH-surge. Key words Postcoital contraceptive - ovulation - pituitary - LH surge

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (6)

Source provenance

openalex
last seen: 2026-05-10T10:46:56.305775+00:00
unpaywall
last seen: 2026-06-06T02:00:05.402940+00:00
License: CC0 · commercial use OK